Ardelyx heads into its third-quarter report with a credibility problem rather than a demand problem. Last quarter the company posted record product revenue, then cut its Ibsrella outlook by about $60 million, withdrew its long-term Exposa target and pushed sustained profitability into 2027. The stock has lost nearly a quarter of its value since. The November 3 release, due after the close, is the first chance to show whether the reset guidance was conservative enough or whether the payer headwinds that forced it are still spreading.

Wall Street expects revenue of about $124.5 million, up 12.8% from $110.3 million a year ago and only modestly above the $120.9 million reported last quarter. That is a sharp slowdown for a company whose flagship drug was growing more than 90% a year as recently as the third quarter of 2025. Consensus calls for a loss of 3 cents a share, narrower than the 7-cent loss last quarter but short of the breakeven result from a year earlier. Management now guides 2026 revenue to $460 million to $490 million, down from $520 million to $550 million. The full-year consensus of roughly $540 million still sits above even the old midpoint, which suggests some forecasts have not caught up with the cut. Expect those numbers to fall toward the new range regardless of how the quarter lands.

The central issue is Ibsrella's trajectory. Growth slowed from 58% in the first quarter to 33% in the second as payers added step edits and tougher prior authorizations that delay new patient starts. Ibsrella brought in about $156 million in the first half. Reaching even the low end of the new $350 million to $370 million range requires an average of roughly $97 million a quarter in the back half, a clear step up from the $86.2 million booked in the second quarter. A third-quarter figure that falls well short of that pace would raise questions about whether a second cut is coming. Evidence that prescriptions are still growing while approvals improve would support management's view that access hurdles slow patients down rather than shut them out.

The company's response deserves equal scrutiny. Ardelyx expanded its sales force to 144 reps, doubled its field reimbursement team and planned a direct-to-consumer campaign for the second half. It also signaled a willingness to offer rebates to payers, reversing a long-held stance. Any discounting would help access but could cut into net price. Revenue that rises on volume while net price slips would be a mixed result. On costs, management promised to hold operating expenses below $500 million, and the narrower loss forecast assumes it can do that while spending on commercial expansion. Investors who noticed the $50 million draw on the company's debt facility will want a clear view of cash runway.

Exposa is the steadier piece. Management has held its $110 million to $120 million forecast for four straight quarters, and second-quarter sales rose 27%. Even so, the end of the Tdapa add-on payment period and a new phosphorus quality measure prompted management to scrap its $750 million peak target. Another reaffirmation would help, but the more useful signal is whether dispensing trends hold up under the new dialysis payment environment.

Sentiment has moved from deeply bearish before the last report to roughly neutral, a sign that much of the bad news may already be priced in. At $3.08, the stock trades far below its 200-day average of $5.44 and just above its post-earnings low of $3.02, a range well under the prior quarter's $4.82 to $7.43. Holding that floor depends on one question: whether Ibsrella's second-half run rate makes the lowered guidance look achievable or optimistic.